Evidence map›Paper›PMID 28004124›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2017

Attenuation of neointimal formation with netrin-1 and netrin-1 preconditioned endothelial progenitor cells.

Norika Mengchia Liu, Kin Lung Siu, Ji Youn Youn, Hua Cai

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Guidance Molecules in Vascular Smooth Muscle.Frontiers in physiology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Norika Mengchia LiuDivisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA, 90095, USA.
Kin Lung SiuDivisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA, 90095, USA.
Ji Youn YounDivisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA, 90095, USA.
Hua CaiDivisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine at University of California Los Angeles, 650 Charles E. Young Drive, Los Angeles, CA, 90095, USA. hcai@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Angiotensin II Uncoupling of Enos in HypertensionR01HL077440 · NHLBI · UNIVERSITY OF CHICAGO · PI CAI, HUA LINDA · 2005 to 2019
$4.8M
NOXs, eNOS Uncoupling and Diabetic AtherogenesisR01HL088975 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA · 2010 to 2019
$4.5M
Endothelium-Myocardium Interaction in Netrin-1 Induced CardioprotectionR01HL119968 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA · 2013 to 2017
$2.5M
Role of Vascular Oxidative Stress in ObesityR01HL108701 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA, HARRISON, DAVID G · 2012 to 2015
$1.9M
NHLBI NIH HHS R01 HL077440NHLBI NIH HHS R01 HL088975NHLBI NIH HHS R01 HL108701NHLBI NIH HHS R01 HL119968
6 · The paper itself

Abstract

Restenosis after angioplasty is a serious clinical problem that can result in re-occlusion of the coronary artery. Although current drug-eluting stents have proved to be more effective in reducing restenosis, they have drawbacks of inhibiting reendothelialization to promote thrombosis. New treatment options are in urgent need. We have shown that netrin-1, an axon-guiding protein, promotes angiogenesis and cardioprotection via production of nitric oxide (NO). The present study examined whether and how netrin-1 attenuates neointimal formation in a femoral wire injury model. Infusion of netrin-1 into C57BL/6 mice markedly attenuated neointimal formation following wire injury of femoral arteries, measured by intimal to media ratio (from 1.94 ± 0.55 to 0.45 ± 0.86 at 4 weeks). Proliferation of VSMC in situ was largely reduced. This protective effect was absent in DCC KEY MESSAGE: Netrin-1 attenuates neointimal formation following post endothelial injury via DCC and NO. Netrin-1 inhibits VSMC proliferation in situ following endothelial injury. Netrin-1 inhibits VSMC migration via a NO/cGMP/p38 MAPK pathway. Netrin-1 augments proliferation of endothelial progenitor cells (EPCs) and EPC eNOS/NO activation. Netrin-1 enhances resistance of EPCs to oxidative stress, improving re-endothelialization following injury.

Indexed as

AnimalsCell LineCell MovementCell ProliferationCells, CulturedDCC ReceptorEndothelial Progenitor CellsHumansMaleMice, Inbred C57BLNeointimaNetrin-1Nitric OxideProtective AgentsRatsSignal TransductionDcc protein, mouseDCC ReceptorNetrin-1Nitric OxideProtective AgentsDeleted in colorectal cancer (DCC)Endothelial nitric oxide synthase (eNOS) phosphorylationEndothelial progenitor cells (EPCs)EPC homingEPC proliferationEPC resistance to oxidative stressFemoral wire injuryNeointimal formationNetrin-1NO productionRe-endothelializationVascular smooth muscle cell (VSMC) proliferationVSMC migration

Identifiers

PMID28004124
PMCPMC5976243
OpenAlexW2565654931

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.